NCT07581431招募中1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of ISM8969 in Healthy Adult and Elderly Participants and Obese Adult Participants at Risk of Cardiovascular Disease
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969 in healthy adults and elderly participants and obese adult participants at risk of cardiovascular disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must meet all the following criteria to be included in the study:
- •Inclusion criteria 1~4 are only for the healthy participants in the SAD and MAD study:
- •Male or female participants, including adult participants (≥18 and <65 years of age) for the SAD cohorts 1-6 and MAD cohorts 1-3, and elderly participants (≥65 and ≤80 years of age) for MAD cohort
- •Body mass index (BMI) >18.5 and <30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
- •Non-smokers (no use of tobacco or nicotine products within 1 month prior to screening).
- •Healthy as defined the current protocol.
- •Inclusion criteria 5~9 are only for the obese participants at risk of cardiovascular disease in MAD study):
- •Male or female, ≥18 and ≤65 years of age.
- •30.0 kg/m2 ≤ BMI < 42.0 kg/m
- •No change in body weight or self-reported change of less than 5.0% within 3 months before screening.
- •Presence of 1 or more risk factors for cardiovascular disease such as hypertension, hyperlipidemia. If present, must be controlled with stable medication dose/therapy (defined as a stable medication dose/therapy for 3 months or longer).
- •hsCRP ≥3 mg/L.
排除标准
- •Participants for whom any of the following applies will be excluded from the study:
- •Columbia suicide severity rating scale (C-SSRS) score above Type 1 ideation.
- •Positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen and antibody, treponema pallidum antibody or QuantiFERON®-TB test at screening.
- •Positive pregnancy test or lactating female participant.
- •History of any central nervous system (CNS) disorder or history of seizure of any cause.
- •Clinically significant 12-lead ECG, physical examination, vital signs or laboratory abnormalities at screening, including but not limited to defined in the protocol.
- •History of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to defined in the protocol.
- •History of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, or in situ carcinomas of the cervix) for less than 5 years; or there is a potential malignancy during screening.
- •Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days (or 5 half-lives, whichever is longer) prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days (or 5 half-lives, whichever is longer) prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
- •Presence of contraindication to lumbar puncture or lumbar catheter as judged by Investigator.
研究组 & 干预措施
Healthy adults in SAD cohorts will receive ISM8969 or placebo orally up to 6 single-dose levels.
Experimental
干预措施: ISM8969 tablets or placebo (Drug)
Healthy adults and elderly participants in MAD cohorts will receive ISM8969 or placebo up to14 days.
Experimental
干预措施: ISM8969 tablets or placebo (Drug)
Obese adult participants will receive ISM8969 or placebo orally up to 14 days.
Experimental
干预措施: ISM8969 tablets or placebo (Drug)
结局指标
主要结局
未指定
次要结局
- Minimal observed concentration at steady-state (Cmin,ss).(Day 14 before the last dose.)
- Minimal observed cerebrospinal fluid(CSF) concentration at steady-state (Cmin,ss).(Day 14 before the last dose.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult ParticipantsDry EyeNCT07521748Nanjing Reju Therapeutics Co., Ltd24
招募中
2 期
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial DiseasePeripheral Arterial DiseaseNCT07318155Sirius Therapeutics Co., Ltd.104
招募中
2 期
A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency SyndromeNCT07432490Oregon Health and Science University16
招募中
1 期
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)NCT07619820CSL Behring24
招募中
2 期
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s DiseaseCTRI/2024/08/072601PSI CRO Pharma India Pvt Ltd210